Otitis Media Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000
Buy Report

Published: March 31, 2022 Report Code: GMDGDHC22025IDB-ST

Select Item

Otitis Media Pipeline Drugs Market Overview

Otitis media (OM) is any inflammation of the middle ear, the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Symptoms include ear pain, difficulty sleeping, loss of balance, fever, headache, and loss of appetite. Risk factors include age, seasonal factors, and exposure to tobacco smoke or high levels of air pollution. Treatment includes antibiotics and antipyrine.

The otitis media drugs in development market research report provides an overview of the Otitis Media pipeline landscape. The report provides comprehensive information on the therapeutics under development for Otitis Media, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects.

What are the targets of the Otitis Media pipeline drugs market?

The targets of the Otitis Media pipeline drugs market are DNA Gyrase, DNA Topoisomerase IV, 23S Ribosomal RNA, Beta Lactamase, DNA Topoisomerase II, Glucocorticoid Receptor, Lymphocyte Antigen 96, and Penicillin Binding Protein.

Otitis Media pipeline drugs market, by targets

Otitis Media pipeline drugs market, by targets

For more target insights, download a free report sample

What are the mechanisms of action of the Otitis Media pipeline drugs market?

Some of the mechanisms of action of the Otitis Media pipeline drugs market are DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, 23S Ribosomal RNA Inhibitor, Beta Lactamase Inhibitor, DNA Topoisomerase II Inhibitor, Glucocorticoid Receptor Agonist, Lymphocyte Antigen 96 Inhibitor, and Penicillin Binding Protein Inhibitor.

Otitis Media pipeline drugs market, by mechanisms of action

Otitis Media pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

What are the routes of administration in the Otitis Media pipeline drugs market?

The routes of administration in the Otitis Media pipeline drugs market are intravenous, oral, auricular (otic), ophthalmic, intramuscular, nasal, subcutaneous, topical, and transtympanic.

Otitis Media pipeline drugs market, by routes of administration

Otitis Media pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

What are the molecule types in the Otitis Media pipeline drugs market?

The molecule types in the Otitis Media pipeline drugs market are small molecule, conjugate vaccine, monoclonal antibody, live attenuated vaccine, and subunit vaccine.

Otitis Media pipeline drugs market, by molecule types

Otitis Media pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Which are the key companies in the Otitis Media pipeline drugs market?

Some of the key companies in the Otitis Media pipeline drugs market are Merck & Co Inc, Clarametyx Biosciences Inc, Olymvax Biopharmaceuticals Inc, Vaxcyte Inc, Blue Water Vaccines Inc, Ceolia Pharma Co Ltd, Earnano LLC, Furen Pharmaceutical Group Co Ltd, Hunan Sanqing Pharmaceutical Co Ltd, and Inventprise LLC.

Otitis Media pipeline drugs market, by key companies

Otitis Media pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report scope

Targets DNA Gyrase, DNA Topoisomerase IV, 23S Ribosomal RNA, Beta Lactamase, DNA Topoisomerase II, Glucocorticoid Receptor, Lymphocyte Antigen 96, and Penicillin Binding Protein
Mechanisms of Action DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, 23S Ribosomal RNA Inhibitor, Beta Lactamase Inhibitor, DNA Topoisomerase II Inhibitor, Glucocorticoid Receptor Agonist, Lymphocyte Antigen 96 Inhibitor, and Penicillin Binding Protein Inhibitor
Routes of Administration  Intravenous, Oral, Auricular (Otic), Ophthalmic, Intramuscular, Nasal, Subcutaneous, Topical, and Transtympanic
Molecule Types Small Molecule, Conjugate Vaccine, Monoclonal Antibody, Live Attenuated Vaccine, and Subunit Vaccine
Key Companies Merck & Co Inc, Clarametyx Biosciences Inc, Olymvax Biopharmaceuticals Inc, Vaxcyte Inc, Blue Water Vaccines Inc, Ceolia Pharma Co Ltd, Earnano LLC, Furen Pharmaceutical Group Co Ltd, Hunan Sanqing Pharmaceutical Co Ltd, and Inventprise LLC

This report provides:

  • A snapshot of the global therapeutic landscape of Otitis Media (Ear Nose Throat Disorders).
  • Reviews of pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Key companies involved in Otitis Media (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • Evaluation of Otitis Media (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Otitis Media (Ear Nose Throat Disorders).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Otitis Media (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

Blue Water Vaccines Inc
Ceolia Pharma Co Ltd
Clarametyx Biosciences Inc
Earnano LLC
Furen Pharmaceutical Group Co Ltd
Hunan Sanqing Pharmaceutical Co Ltd
Inventprise LLC
Laboratorios Salvat SA
Maxwell Biosciences Inc
Merck & Co Inc
MerLion Pharmaceuticals Pte Ltd
MyX Therapeutics Inc
NTC srl
O-Ray Pharma Inc
Olymvax Biopharmaceuticals Inc
ProclaRx LLC
Vaxcyte Inc
Vyome Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Otitis Media – Overview

Otitis Media – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Otitis Media – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Otitis Media – Companies Involved in Therapeutics Development

Blue Water Vaccines Inc

Ceolia Pharma Co Ltd

Clarametyx Biosciences Inc

Earnano LLC

Furen Pharmaceutical Group Co Ltd

Hunan Sanqing Pharmaceutical Co Ltd

Inventprise LLC

Laboratorios Salvat SA

Maxwell Biosciences Inc

Merck & Co Inc

MerLion Pharmaceuticals Pte Ltd

MyX Therapeutics Inc

NTC srl

O-Ray Pharma Inc

Olymvax Biopharmaceuticals Inc

ProclaRx LLC

Vaxcyte Inc

Vyome Therapeutics Inc

Otitis Media – Drug Profiles

(ciprofloxacin hydrochloride + fluocinolone acetonide) – Drug Profile

Product Description

Mechanism Of Action

History of Events

aspoxicillin – Drug Profile

Product Description

Mechanism Of Action

BWV-201 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CMTX-200 – Drug Profile

Product Description

Mechanism Of Action

CMTX-301 – Drug Profile

Product Description

Mechanism Of Action

Drug for Otitis Media – Drug Profile

Product Description

Mechanism Of Action

Drugs for Otitis Media – Drug Profile

Product Description

Mechanism Of Action

ENT-103 – Drug Profile

Product Description

Mechanism Of Action

History of Events

finafloxacin – Drug Profile

Product Description

Mechanism Of Action

History of Events

IVT-25 – Drug Profile

Product Description

Mechanism Of Action

NTC-011 – Drug Profile

Product Description

Mechanism Of Action

OR-404IT – Drug Profile

Product Description

Mechanism Of Action

History of Events

PCL-1440 – Drug Profile

Product Description

Mechanism Of Action

History of Events

pneumococcal (13-valent) vaccine – Drug Profile

Product Description

Mechanism Of Action

pneumococcal (23-valent) vaccine – Drug Profile

Product Description

Mechanism Of Action

pneumococcal polysaccharide [15-valent] vaccine – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules for Chronic Suppurative Otitis Media (CSOM) – Drug Profile

Product Description

Mechanism Of Action

History of Events

solithromycin – Drug Profile

Product Description

Mechanism Of Action

History of Events

tebipenem pivoxil – Drug Profile

Product Description

Mechanism Of Action

Vaccine for Otitis Media – Drug Profile

Product Description

Mechanism Of Action

VAX-24 – Drug Profile

Product Description

Mechanism Of Action

VAX-XP – Drug Profile

Product Description

Mechanism Of Action

VT-1917 – Drug Profile

Product Description

Mechanism Of Action

Otitis Media – Dormant Projects

Otitis Media – Discontinued Products

Otitis Media – Product Development Milestones

Featured News & Press Releases

Dec 20, 2021: Clarametyx Biosciences awarded $3.15 million grant from NIH to advance a broad-spectrum vaccine technology for bacterial infections

Oct 04, 2021: Lee’s Pharmaceutical Holdings: Voluntary announcement – Update on the commercialisation and research and development of Cetraxal Plus of the group

Sep 01, 2021: NanoCarrier : Accomplishment of primary endpoint in phase III clinical study of ENT103

May 31, 2021: NanoCarrier : Completion of patient enrollment for phase III trial with ENT103

Jan 13, 2021: Lee’s Pharmaceutical Holdings: Voluntary announcement update on an investigational ear drug product

Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempra’s Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media

May 18, 2017: Pediapharm Announces the Commercial Launch of Otixal in Canada

Dec 27, 2016: OTOVEL’s trials published in JAMA

Dec 12, 2016: Pediapharm receives Health Canada approval for Otixal

Sep 29, 2014: SALVAT announces positive top-line results from two Phase III studies of its novel otic antibiotic/steroid combination solution in the treatment of AOMT with Tympanostomy tubes

May 28, 2013: Salvat Completes Enrollment Of Phase III Study For New Combination In Acute Otitis Media In Pediatric Patients With Tympanostomy Tubes

Apr 18, 2012: MerLion Initiates Phase III Clinical Program To Evaluate Finafloxacin For Treatment Of Acute Otitis Media

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Otitis Media, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Otitis Media – Pipeline by Blue Water Vaccines Inc, 2022

Otitis Media – Pipeline by Ceolia Pharma Co Ltd, 2022

Otitis Media – Pipeline by Clarametyx Biosciences Inc, 2022

Otitis Media – Pipeline by Earnano LLC, 2022

Otitis Media – Pipeline by Furen Pharmaceutical Group Co Ltd, 2022

Otitis Media – Pipeline by Hunan Sanqing Pharmaceutical Co Ltd, 2022

Otitis Media – Pipeline by Inventprise LLC, 2022

Otitis Media – Pipeline by Laboratorios Salvat SA, 2022

Otitis Media – Pipeline by Maxwell Biosciences Inc, 2022

Otitis Media – Pipeline by Merck & Co Inc, 2022

Otitis Media – Pipeline by MerLion Pharmaceuticals Pte Ltd, 2022

Otitis Media – Pipeline by MyX Therapeutics Inc, 2022

Otitis Media – Pipeline by NTC srl, 2022

Otitis Media – Pipeline by O-Ray Pharma Inc, 2022

Otitis Media – Pipeline by Olymvax Biopharmaceuticals Inc, 2022

Otitis Media – Pipeline by ProclaRx LLC, 2022

Otitis Media – Pipeline by Vaxcyte Inc, 2022

Otitis Media – Pipeline by Vyome Therapeutics Inc, 2022

Otitis Media – Dormant Projects, 2022

Otitis Media – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Otitis Media, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Otitis Media Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Ear Nose Throat Disorders reports
Pharmaceuticals
New
New Drug Approvals and Their Contract Manufacture - 2024 Edition
$4,995 | April 2024
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Otitis Media Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Otitis Media Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more